Key Takeaways
- Strong Q1, guidance raised: Revenue grew 20.1% YoY with India returning to double digits and international surging 34.2%, prompting management to signal comfort at the higher end of its low-to-mid-teens FY27 guidance.
- International is the margin story: Export-led growth compressed gross margin to an expected ~59% for the year, but the same mix lifted EBITDA margin 50 bps to 19.7% because B2B channels are EBITDA-accretive.
- Zuventus has turned the corner: After a painful restructuring, the subsidiary has moved through stability and consolidation into an acceleration phase, removing a drag on domestic organic growth.
- The semaglutide bet is live but unproven: Poviztra is cleared for MASH and management believes the innovator tie-up is a strategic edge, yet with 40–50 brands launching, the company admits the jury will be out for 3–6 months.
- What to watch next quarter: Whether domestic organic growth (6–7% in Q1) accelerates to industry-level or above as promised, the pace of Zuventus's acceleration, and the net debt jump toward ~₹1,450 crore after Mantra and Gennova payouts.
India Business: Recovery and the Zuventus Turnaround
- Double-digit return: India business grew 10.2% YoY after a soft Q4 FY26, with management calling the growth normalized and free of channel filling. Leading brands in CNS, cardiology and gynaecology drove the recovery.
- Organic growth still catching up: Stripping out in-licensed products from Sanofi, Roche and Novo Nordisk, organic domestic growth was about 6–7% in Q1, weighed down by the Zuventus consolidation. Management expects this to align with industry growth from Q2 and outpace it in the second half.
- Three in-licensing levers: Products from Sanofi (OAD portfolio), Roche, and Poviztra (semaglutide) from Novo Nordisk complemented the company's own brands and broadened therapy-area presence, with Poviztra providing a solid entry into the obesity market.
- Zuventus restructuring complete: The subsidiary has moved through three deliberate phases: stability, normalization and consolidation. Management now says it is moving toward acceleration, with a good team in place and the drag on domestic performance behind it.
- Domestic strategy intact: Three levers underpin the outlook: making big brands bigger, in-licensing from multinationals and ICMR, and leveraging R&D-developed products such as ferrous ascorbate, ferric carboxymaltose, chiral compounds and Tenecteplase.
Satish Mehta: "I had made a very interesting statement, Alankar, there are 3 phases. First, I told you about stability, consolidation acceleration. These are the 3 very specific terms I used. So, as I told you in the last quarter, we had a problem. We had attrition as far as Zuventus is concerned. So now the stability has come back, normalization has taken place. consolidation has also happened and now we are moving towards acceleration."
International Business: The Growth Engine
- Broad-based surge: International revenue grew 34.2% YoY, with all regions contributing. The performance was supported by base-business ramp-up, new launches and currency tailwinds.
- Europe grew 32.8% YoY, led by strong base-business performance and an enhanced contribution from liposomal amphotericin B, which has now been introduced in pretty much all countries with supplies ramping up. The bolt-on Manx acquisition in the U.K. also contributed, with most products now commercialized.
- Canada grew 24.6% YoY, with continued base-business growth driven by new launches and market-share gains, supported by a robust product pipeline.
- Rest of the World grew 44.8% YoY, led by very strong ARV performance. ARV was about two-thirds of ROW revenue in Q1, though the full-year mix is expected at 50–55% ARV. Non-ARV momentum also continued.
- Semaglutide Canada filing is planned for the current quarter, with launch expected in the second wave. Management is not banking on it as a meaningful growth driver, treating it as one portfolio product among many.
Margins: Mix-Driven Compression and Expansion
- Gross margin declined YoY, a function of product and business mix as higher exports, particularly in Europe and ARV, carry lower gross margins because they are more B2B in nature. Management expects full-year gross margin around 59% given the strength in international business, versus an earlier expectation of 60% to 61%.
- EBITDA margin improved 50 bps to 19.7%, reflecting benefits of scale, operating leverage, productivity gains and disciplined cost management. The same B2B channels that compress gross margin are EBITDA-accretive at the operating level.
- PAT grew faster than revenue at 35.4–36.2% YoY, underlining the strength of operating performance and improved profitability.
- R&D spend was ₹90 crore (3.5% of revenue) in Q1 and is expected to pick up through the remainder of the fiscal year, landing in the 4–5% range for FY27.
- Net debt increased from Q4 to Q1 on slightly higher working capital, which has now stabilized and is expected to normalize in the current quarter. However, net debt will rise further next quarter to close to ₹1,450 crore, reflecting Mantra and Gennova payouts completed in July. Management expects to turn net cash by end of FY28, from a current net debt of ₹1,103 crore.
Semaglutide: A Contested Opportunity
- Poviztra cleared for MASH: The product received clearance for metabolic dysfunction-associated steatohepatitis 15 days prior to the call, and the company is now approaching hepatologists and gastroenterologists. Month-over-month growth is visible.
- Crowded field: Management estimates 40–50 brands are being launched in the Indian semaglutide market, making it difficult to separate channel stocking from actual consumption. The company expects it will take 3–6 months for the market picture to clarify.
- Competitive positioning: Management believes the association with the innovator (Novo Nordisk) is a strategic advantage, citing the rDNA molecule, extensive clinical-trial data and publications, and competitive pricing. The stated view is that it will be a question of survival of the fittest.
- Canada launch timing: Filing is imminent, but the launch will be in the second wave and depends on how supplies from partner Dr. Reddy's shape up. Management deferred to Reddy's on specific timelines.
Satish Mehta: "I don't have a crystal ball here... the jury is out, wait for 3 to 6 months before we know what's really going on because I'm given to understand almost 40, 50 brands are being launched. At this stage, it is difficult to assess how much of this is channel stocking and how much represents actual consumption, so I would not like to hazard a guess."
Pipeline, Licensing and Structural Simplification
- Gennova now wholly owned: The company acquired the 12.05% minority stake in Gennova, making it a 100% owned subsidiary. All Indian and foreign subsidiaries, including Zuventus, are now fully owned by the parent, creating a simplified and aligned group structure.
- ICMR anti-HPV license: In July, ICMR licensed a novel anti-HPV candidate for Cervical Intraepithelial Neoplasia to Emcure as part of a government technology-transfer initiative. The product is an NCE and part of the women's healthcare portfolio, but it will need to go through various development phases.
- MSD voluntary license for HIV PrEP: The company signed a royalty-free, non-exclusive voluntary licensing agreement with Merck Sharp & Dohme to manufacture and sell a generic version of alimatravir, an experimental once-a-month oral HIV pill, across 129 low and lower-middle-income countries. The drug is currently in late-stage development.
- Board and leadership changes: Chairman Berjis Desai will step down at the conclusion of the AGM after being appointed to the National Commission for Minorities. Satish Mehta will take on the role of Chairman in addition to his existing MD and CEO role. Samit Mehta has been appointed COO with broader oversight of group R&D, manufacturing operations and licensing activities, while continuing as CEO of Gennova.
Satish Mehta: "I assure all of you that company strategy, operations, execution, everything remains unchanged."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Low to mid-teen; management more comfortable at the higher end | FY27 |
| EBITDA margin expansion | 70 to 100 bps | FY27 |
| India organic growth | At par or faster than industry growth | Full year FY27 |
| India quarterly trajectory | Northward movement quarter after quarter (Q2, Q3, Q4) | FY27 |
| Zuventus | Moving from consolidation to acceleration phase | Going forward |
| Gross margin | Around 59% to 60% | FY27 |
| R&D spend | 4% to 5% of revenue | FY27 |
| Net debt | Increase to close to ~₹1,450 crore from what today I see at ₹1,560 crore reflecting Mantra and Gennova payouts | Next quarter (Q2 FY27) |
| Net cash | Turn net cash positive | By end of FY28 |
| Semaglutide Canada filing | File in the current quarter | Next few months |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹2,580 cr, +22.8% YoY |
| EBITDA | ₹508 cr, +25.8% YoY |
| EBITDA margin | 19.7%, +50 bps YoY |
| Profit after tax | ₹292 cr, +36.2% YoY |
| PAT margin | improved 110 bps YoY |
| Gross profit | ₹1,507 cr, +16.1% YoY |
| Gross margin | 58.4%, declined YoY; FY27 guidance ~59% |
| R&D spend | ₹90 cr, 3.5% of revenue; FY27 guidance 4%–5% |
| India business revenue | ₹1,095 cr, +10.2% YoY and +12% vs Q4 FY26 |
| India organic growth | ~6%–7% (stripping Sanofi OAD and Roche) |
| International business revenue | ₹1,485 cr, +34.2% YoY |
| Europe revenue | ₹537 cr, +32.8% YoY |
| Canada revenue | ₹427 cr, +24.6% YoY |
| Rest of World revenue | ₹522 cr, +44.8% YoY |
| ARV share of ROW revenue | ~2/3 in Q1; full-year expected 50%–55% |
| Constant currency growth, international | ~12% (per an analyst's math) |
| Net debt | ₹1,103 cr as of June 30; expected ~₹1,450 cr next quarter |
| Gross debt | ₹1,291 cr as of June 30 |
| Cash and equivalents | ₹189 cr as of June 30 |
| Depreciation and amortization | ₹110 cr, up from ₹99 cr in Q1 FY26 |
| Interest cost | ₹32 cr |
| Effective tax rate | 25.6% |
| Product approvals in quarter | 15-plus across developed and emerging markets |
| FY27 revenue growth guidance | low to mid-teen; management comfortable at higher end |
| FY27 EBITDA margin expansion guidance | 70–100 bps |
| Net cash expected | by end of FY28 |